Feb 26 (Reuters) – Britain’s Hikma Pharmaceuticals on Thursday forecast slower annual revenue growth, withdrew its medium-term targets, and said CEO Said Darwazah would step down as executive chairman to focus on turning around the drugmaker.
The forecast signals continuing difficulty for the generic drug manufacturer, which, along with its peers, faces margin pressure and rising competition on high-value U.S. injectable products.
Hikma forecast group revenue growth of 2% to 4% for 2026, down from 7% it achieved in 2025.
The company expects core operating profit between $720 million and $770 million, compared with $741 million for 2025.
The firm said it expects full commercial production at its Bedford manufacturing plant to start in 2028.
(Reporting by Sri Hari N S in Bengaluru; Editing by Sumana Nandy and Mrigank Dhaniwala)
Comments